Are you a Health Professional? Jump over to the doctors only platform. Click Here

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients with Moderate to Severe Active Rheumatoid Arthritis

Print Friendly, PDF & Email

This randomised, double-blind, parallel group study will compare the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis. Patients will be randomised to receive either RoActemra/Actemra 162 mg sc weekly plus iv placebo every 4 weeks, or RoActemra/Actemra 8 mg/kg iv every 4 weeks plus sc placebo weekly during the double-blind period from baseline to Week 24. The double-blind period will be followed by a 72-week open-label treatment with some switching of sc and iv administration. No placebo will be administered in the open-label phase. Patients will continue on their stable dose of disease-modifying anti-rheumatic drugs (DMARDs) throughout the study. Anticipated time on study treatment is 2 years.

Official Title

Randomised, Double-blind, Parallel Group Study Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis


Rheumatoid Arthritis

Study Type


Study Design

Allocation: Randomised
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Further Details

Primary Outcome Measures:

  • Proportion of patients achieving clinical improvement of 20% according to American College of Rheumatology criteria (ACR20) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Safety comparison of sc versus iv administration: Adverse events and laboratory assessments [ Time Frame: through to study end (up to 4 years) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

  • Long-term efficacy according to American College of Rheumatology criteria (ACR20, ACR50, ACR70) [ Time Frame: 97 weeks ] [ Designated as safety issue: No ]
  • Long-term efficacy according to Disease Activity Score (DAS28) [ Time Frame: 97 weeks ] [ Designated as safety issue: No ]
  • Long-term efficacy according to the Health Assessment Questionnaire Disability Index (HAQ-DI) [ Time Frame: 97 weeks ] [ Designated as safety issue: No ]
  • Pharmacokinetics (AUC, Cmax, Tmax) and Pharmacodynamics (interleukin-6, soluble interleukin-6 receptor) of tocilizumab after sc administration [ Time Frame: 97 weeks ] [ Designated as safety issue: No ]
  • Immunogenicity of tocilizumab (TCZ) following sc administration: anti-TCZ antibodies [ Time Frame: 97 weeks ] [ Designated as safety issue: No ]
  • Effect of switch from iv to sc administration (efficacy, safety, PK, PD) [ Time Frame: from week 25 to week 97 ] [ Designated as safety issue: No ]


Arm                                                                     Intervention


SC: Experimental                                             Drug: tocilizumab

Interventions:                                                     [RoActemra/Actemra]

                                                                         162 mg subcutaneously weekly

  • Drug: tocilizumab                                  Drug: placebo
    [RoActemra/Actemra]                             intravenously weekly, 24 weeks
  • Drug: placebo                                       Drug: Disease-modifying
  • Drug: Disease-modifying                        anti-rheumatic drugs (DMARDs)
    anti-rheumatic drugs (DMARDs)               stable dose as prescribed



IV: Active Comparator                                     Drug: tocilizumab

Interventions:                                                [RoActemra/Actemra]

  • Drug: tocilizumab                                 8 mg/kg intravenously every 4
    [RoActemra/Actemra]                            weeks
  • Drug: placebo                                      Drug: placebo
  • Drug: Disease-modifying                       subcutaneously every 4 weeks for
    anti-rheumatic drugs (DMARDs)              24 weeks

                                                                    Drug: Disease-modifying

                                                                    anti-rheumatic drugs (DMARDs)

                                                                    stable dose as prescribed

Study Start

September 2010 – February 2014

Eligibility & Criteria

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No


Inclusion Criteria:

  • Adult patients, >/=18 years of age
  • Rheumatoid arthritis of >/= 6 months duration, according to American College of Rheumatology (ACR) criteria
  • Swollen joint count (SJC) >/= 4 (66 joint count), tender joint count (TJC) >/= 4 (68 joint count) at screening and baseline
  • Inadequate response to current DMARD therapy
  • Permitted DMARDs must be at stable dose for >/= 8 weeks prior to baseline
  • Oral corticosteroids (</= 10 mg/day prednisone or equivalent) and NSAIDs (up to maximum recommended dose) must be at stable dose for >/= 4 weeks prior to baseline


Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization
  • Rheumatic autoimmune disease other than RA
  • Functional class IV (ACR classification)
  • Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis (JRA) and/or RA before the age of 16
  • Prior history of or current inflammatory joint disease other than RA
  • Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline
  • Previous treatment with RoActemra/Actemra
  • Active current or history of recurrent infection

Total Enrolment


Contact Details

Print Friendly, PDF & Email


Posted On: 1 January, 2013
Modified On: 16 September, 2014


Created by: myVMC